Inicio › Linfoma difuso de células B grandes › Texas › Houston
Ensayos clínicos de Linfoma difuso de células B grandes en Houston, TX
17 estudios para Linfoma difuso de células B grandes buscan participantes en centros de Houston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
ReclutandoFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutandoFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
ReclutandoFase 1
- Md Anderson Cancer Center, Houston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ReclutandoFase 2
- MD Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ReclutandoFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutandoFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutandoFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
ReclutandoFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutandoEstudio observacional
- Texas Children's Hospital, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
ReclutandoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
ReclutandoFase 1
- MD Anderson Cancer Center, Houston
Ensayos de Linfoma difuso de células B grandes en otras ciudades
- New York City, NY21 estudios
- Baldwin Park, CA19 estudios
- Chicago, IL18 estudios
- Los Angeles, CA17 estudios
- Milwaukee, WI16 estudios
- Boston, MA16 estudios
- Philadelphia, PA15 estudios
- Portland, OR15 estudios
- Durham, NC14 estudios
- Nashville, TN14 estudios
- Dallas, TX13 estudios
- Seattle, WA12 estudios
Otros estudios en Houston
- Cáncer de pulmón de células no pequeñas145 estudios
- Cáncer de seno126 estudios
- Cáncer (todos los tipos)123 estudios
- Cáncer metastásico104 estudios
- Cáncer del colon y del recto102 estudios
- Cáncer de ovario89 estudios
- Leucemia mielógena aguda86 estudios
- Cáncer de pulmón78 estudios
- Cáncer de próstata76 estudios
- Cáncer de endometrio68 estudios
- Cáncer de páncreas62 estudios
- Melanoma59 estudios
De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.